about
Clinical development of gene therapy: results and lessons from recent successesIssues in assessing products for the treatment of hemophilia - the intersection between efficacy, economics, and ethics.Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice.An Immune-Competent Murine Model to Study Elimination of AAV-Transduced Hepatocytes by Capsid-Specific CD8+ T CellsEffects of FVIII immunity on hepatocyte and hematopoietic stem cell-directed gene therapy of murine hemophilia A.Progress and challenges in viral vector manufacturingSuperior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid.Syngeneic AAV Pseudo-particles Potentiate Gene Transduction of AAV Vectors.Potential for cellular stress response to hepatic factor VIII expression from AAV vectorComplexity of immune responses to AAV transgene products - Example of factor IX.Regulatory T cells and TLR9 activation shape antibody formation to a secreted transgene product in AAV muscle gene transfer.Immune Modulatory Cell Therapy for Hemophilia B Based on CD20-Targeted Lentiviral Gene Transfer to Primary B Cells.An Exon-Specific U1snRNA Induces a Robust Factor IX Activity in Mice Expressing Multiple Human FIX Splicing Mutants.Microfluidic Transduction Harnesses Mass Transport Principles to Enhance Gene Transfer Efficiency.Novel approaches to hemophilia therapy: successes and challenges.Gene Therapy for Hemophilia.Emerging therapies for hemophilia: controversies and unanswered questions.
P2860
Q26743393-7070F3F2-B54B-4B9B-B1A5-B2265EFB4EBAQ35766551-06149412-06C5-40A9-97DE-20D71B99BDF9Q36083396-51A3F0C4-F398-4EB9-BC5D-DA678DCD57F5Q36365372-4B5B222B-A12F-4F5A-A415-23A2799A756CQ36571141-FA3FAE9F-E503-44E5-B0A4-A63A5B00EF9BQ36713761-4ED23C76-38E9-451D-A58D-7ECDA347EB5FQ37043507-D4223C5F-2412-490D-9962-5239F4384A7EQ37717907-E7E03DF1-51F4-4DAC-AC0A-F9D657339F3BQ39293496-12397390-CAE5-4506-B21D-D76D46951271Q39394803-7F1770E7-5E03-4C48-AE14-4CDE069708A4Q40049410-3DD29133-A190-414A-8A2E-A1287E0B6258Q40211579-2ACDEB8A-4B40-41FA-AEB7-4E2446DD7AF2Q41671484-35F966D8-1B23-4382-8653-341932D9D818Q45870461-D0F60446-8AAB-4499-80ED-28095FC254DEQ45873013-FE26B9BB-F8D6-4717-93AD-FE7C411B193AQ51057724-08D789EA-6343-4402-AFE8-3ECF303DA0EFQ54958581-9981F17B-7A3C-4E62-99E9-D66DC38B5F74
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Gene therapy for hemophilia
@ast
Gene therapy for hemophilia
@en
Gene therapy for hemophilia
@nl
type
label
Gene therapy for hemophilia
@ast
Gene therapy for hemophilia
@en
Gene therapy for hemophilia
@nl
prefLabel
Gene therapy for hemophilia
@ast
Gene therapy for hemophilia
@en
Gene therapy for hemophilia
@nl
P2860
P3181
P356
P1476
Gene therapy for hemophilia
@en
P2093
Geoffrey L Rogers
Roland W Herzog
P2860
P304
P3181
P356
10.2741/4324
P407
P577
2015-01-01T00:00:00Z